Racial Differences Seen in Financial Hardship Among Older Cancer Survivors
Income and area-level disadvantage are the largest contributors to racial differences
ISTH Issues Clinical Practice Guideline for the Treatment of Hemophilia
Prophylaxis recommended over episodic treatment of bleeding events for severe and moderately severe hemophilia A and B
Amivantamab-Lazertinib Ups Survival in EGFR-Mutated Advanced Lung Cancer
Improved progression-free survival seen for amivantamab-lazertinib versus osimertinib as first-line treatment
Liberal Transfusion Strategy Not Beneficial for Patients With TBI, Anemia
No significant change seen in unfavorable neurologic outcome as assessed by score on GOS-E at six months
NCCN: Cancer Drug Shortages Remain a Challenge for Clinicians
89 percent of cancer centers report that cancer drugs are in short supply, most often vinblastine, etoposide, and topotecan
Precision-Guided Treatment Improves Outcomes for High-Risk Pediatric Cancer
Improvement in two-year progression-free survival seen with PGT versus standard of care or targeted agents not guided by molecular findings
Survival Improves With Open Hysterectomy for Cervical Cancer
Lower rate of disease-free survival and overall survival seen for minimally invasive versus open hysterectomy
Guidelines Address RT for Management of HPV-Linked Oropharyngeal Cancer
Tailored recommendations presented to maximize survival and minimize side effects
Immunoglobulin Replacement Therapy Beneficial for Blood Cancers
Reduction seen in hypogammaglobulinemia, infections or severe infections, and associated antimicrobial use
PIK3CA Could Guide Use of COX-2 Inhibitors in Treatment for Colon Cancer
Patients with stage III resected colon cancer with PIK3CA gain-of-function mutations treated with celecoxib had improved DFS, OS
